Articles related to URINARY TRACT INFECTION (UTI)

A nationwide surveillance study identified widespread community reservoirs of multidrug-resistant Klebsiella pneumoniae associated with recurrent urinary tract infections and antibiotic resistance.

A randomized noninferiority trial found that oral fosfomycin matched continued intravenous therapy in stabilized patients with ESBL complicated UTIs after 3 to 7 days of initial IV treatment.

The FDA approved cefepime-zidebactam (Zaynich) for complicated UTI and pyelonephritis caused by susceptible gram-negative organisms. Approval followed phase 3 trial data showing higher rates of symptom and microbiologic resolution compared with meropenem in hospitalized adults.

Cotrimoxazole was associated with nearly twice the adverse event rate of fluoroquinolones in a retrospective study of 228 hospitalized men aged 75 or older with urinary tract infections, with acute kidney injury onset occurring at a median of six days post-initiation.

A validated clinical prediction tool demonstrated high accuracy for identifying UTIs in febrile infants and toddlers, offering evidence‑based support for urine testing decisions in pediatric emergency care.

The guidelines discourage bag specimen cultures due to contamination risk and recommend catheterized collection for accurate diagnosis in young children.